Skip to content

Cellectar Biosciences, Inc.

CLRB

CIK 0001279704

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$22.15M
+51.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$10.43
+80.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$34.84M
Q1 May 2026
Cash
$8.35M
Q1 May 2026
Total Debt
$330.22K
Q1 May 2026
Shares Outstanding
7.99M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings